Recombinant human erythropoietin (rhEPO) and darbepoetin α (DPO) are protein-based
drugs for the treatment of anemia by stimulating red blood cell production. Consequently, they …

Using data over 1992Q1–2000Q1, the authors evaluate the ability of various publicly
available mutual fund attributes to explain subsequent domestic equity fund returns. Risk and …

GPR40 is a G-protein-coupled receptor which mediates fatty acid-induced glucose-stimulated
insulin secretion from pancreatic beta cells and incretion release from enteroendocrine …

The recent COVID-19 pandemic underscored the limitations of currently available direct-acting
antiviral treatments against acute respiratory RNA-viral infections and stimulated major …

… Riepe, CFA, is senior vice president at Charles Schwab, San Francisco. Fran Xu, CFA, is
senior research analyst at Charles Schwab, San Francisco. …

GPR40 partial agonism is a promising new mechanism for the treatment of type 2 diabetes
mellitus with clinical proof of concept. Most of the GPR40 agonists in the literature have a …

Valdecoxib is a potent COX‐2 inhibitor. During metabolism studies of valdecoxib by liquid
chromatography/tandem mass spectrometry, we observed a novel mass spectral …

RESULTS • Treatment with PD-1/PD-L1 monoclonal antibodies combined with antiangiogenic
VEGF/R inhibitors shows significant benefit in better overall and progression-free survival …

In this paper, we allow an expert with moral hazard to have private information on what
would happen to his client both with his service and without his service. The contingent …

Objective —To investigate the pharmacokinetics and behavioral effects of aminorex administered
IV and PO in horses. Animals —7 Thoroughbreds. Procedures —In a cross-over design…